Daniel Peckham

List of Publications by Year
in descending order

127	4,730	117625	106344
papers	citations	34 h-index	65 g-index

135	135	135	5671
all docs	docs citations	times ranked	citing authors

#	Article	IF	Citations
1	Ways of coping and survival in Cystic Fibrosis: a 20-year longitudinal study. Journal of Cystic Fibrosis, 2023, 22, 112-118.	0.7	2
2	Smartphone pedometers in adults with asthma: a practical approach to physical activity assessment? A pilot validation study. Journal of Asthma, 2022, 59, 967-975.	1.7	2
3	Cystic fibrosis-related diabetes (CFRD) and cognitive function in adults with cystic fibrosis. Journal of Cystic Fibrosis, 2022, 21, 519-528.	0.7	4
4	Incidence and risk factors of cancer in individuals with cystic fibrosis in the UK; a case-control study. Journal of Cystic Fibrosis, 2022, 21, 302-308.	0.7	14
5	Urinary bicarbonate and metabolic alkalosis during exacerbations in cystic fibrosis. ERJ Open Research, 2022, 8, 00669-2021.	2.6	4
6	Dose adjustments of Elexacaftor/Tezacaftor/Ivacaftor in response to mental health side effects in adults with cystic fibrosis. Journal of Cystic Fibrosis, 2022, 21, 1061-1065.	0.7	37
7	Average rate of lung function decline in adults with cystic fibrosis in the United Kingdom: Data from the UK CF registry. Journal of Cystic Fibrosis, 2021, 20, 86-90.	0.7	19
8	Long-term safety and efficacy of tezacaftorâ€“ivacaftor in individuals with cystic fibrosis aged 12 years or older who are homozygous or heterozygous for Phe508del CFTR (EXTEND): an open-label extension study. Lancet Respiratory Medicine,the, 2021, 9, 733-746.	10.7	33
9	Neurodegenerative Disease and the NLRP3 Inflammasome. Frontiers in Pharmacology, 2021, 12, 643254.	3.5	107
10	The Perils and Pitfalls of Esophageal Dysmotility in Idiopathic Pulmonary Fibrosis. American Journal of Gastroenterology, 2021, 116, 1189-1200.	0.4	8
11	Higher throughput drug screening for rare respiratory diseases: Readthrough therapy in primary ciliary dyskinesia. European Respiratory Journal, 2021, 58, 2000455.	6.7	13
12	Nutritional status and intake in patients with non-cystic fibrosis bronchiectasis (NCFB) - a cross sectional study. Clinical Nutrition, 2021, 40, 5162-5168.	5.0	1
13	Hydrocephalus and diffuse choroid plexus hyperplasia in primary ciliary dyskinesia-related MCIDAS mutation. Neurology: Genetics, 2020, 6, e482.	1.9	24
14	Current and future management of non-tuberculous mycobacterial pulmonary disease (NTM-PD) in the UK. BMJ Open Respiratory Research, 2020, 7, e000591.	3.0	14
15	The global impact of SARS-CoV-2 in 181 people with cystic fibrosis. Journal of Cystic Fibrosis, 2020, 19, 868-871.	0.7	74
16	Dysregulated signalling pathways in innate immune cells with cystic fibrosis mutations. Cellular and Molecular Life Sciences, 2020, 77, 4485-4503.	5.4	42
17	COVID-19 meets Cystic Fibrosis: for better or worse?. Genes and Immunity, 2020, 21, 260-262.	4.1	39
18	Oral cysteamine as an adjunct treatment in cystic fibrosis pulmonary exacerbations: An exploratory randomized clinical trial. PLoS ONE, 2020, 15, e0242945.	2.5	10

#	Article	IF	Citations
19	Different CFTR modulator combinations downregulate inflammation differently in cystic fibrosis. ELife, 2020, 9, .	6.0	75
20	Metabolic Reprograming of Cystic Fibrosis Macrophages via the IRE1Î± Arm of the Unfolded Protein Response Results in Exacerbated Inflammation. Frontiers in Immunology, 2019, 10, 1789.	4.8	41
21	Cystic Fibrosis Diagnosis in Newborns, Children, and Adults. Seminars in Respiratory and Critical Care Medicine, 2019, 40, 701-714.	2.1	16
22	Assessing arthritis in the context of cystic fibrosis. Pediatric Pulmonology, 2019, 54, 770-777.	2.0	10
23	Level of accuracy of diagnoses recorded in discharge summaries: A cohort study in three respiratory wards. Journal of Evaluation in Clinical Practice, 2019, 25, 36-43.	1.8	21
24	Use of ceftazidime/avibactam for the treatment of MDR Pseudomonas aeruginosa and Burkholderia cepacia complex infections in cystic fibrosis: a case series. Journal of Antimicrobial Chemotherapy, 2019, 74, 1425-1429.	3.0	23
25	Respiratory morbidity in young people surviving cancer: Populationâ€based study of hospital admissions, treatmentâ€related risk factors and subsequent mortality. International Journal of Cancer, 2019, 145, 20-28.	5.1	15
26	Serum IgE and IgG reactivity to Aspergillus recombinant antigens in patients with cystic fibrosis. Journal of Medical Microbiology, 2019, 68, 924-929.	1.8	10
27	ENaC-mediated sodium influx exacerbates NLRP3-dependent inflammation in cystic fibrosis. ELife, 2019, 8, .	6.0	70
28	Use of NIV in cystic fibrosis: 10-year experience of a large adult CF centre. , 2019, , .		0
29	Do CT findings of Mycobacterium abscessus infection in patients with Cystic Fibrosis predict outcome?. , 2019, , .		0
30	Outcomes at 6 months following NIV in adults with cystic fibrosis (CF): experience of a large UK centre. , 2019, , .		0
31	Autoinflammatory disease in the lung. Immunology, 2018, 154, 563-573.	4.4	25
32	Intravenous fosfomycin for pulmonary exacerbation of cystic fibrosis: Real life experience of a large adult CF centre. Pulmonary Pharmacology and Therapeutics, 2018, 50, 82-87.	2.6	6
33	The impact of three discharge coding methods on the accuracy of diagnostic coding and hospital reimbursement for inpatient medical care. International Journal of Medical Informatics, 2018, 115, 35-42.	3.3	17
34	Î²-Lactam hypersensitivity involves expansion of circulating and skin-resident TH22Âcells. Journal of Allergy and Clinical Immunology, 2018, 141, 235-249.e8.	2.9	34
35	112â€ƒMusculoskeletal symptoms represent a significant burden for adults with cystic fibrosis. Rheumatology, 2018, 57, .	1.9	1
36	Regulation of the Unfolded Protein Response in Disease: Cellular Stress and microRNAs. Current Immunology Reviews, 2018, 14, 3-14.	1.2	1

#	Article	IF	Citations
37	Cytomegalovirus-associated pulmonary exacerbation in patients with cystic fibrosis. ERJ Open Research, 2018, 4, 00111-2017.	2.6	2
38	A new score to identify patients who need fitness to fly test. , 2018, , .		0
39	Can serum bicarbonate be used to screen for sleep disordered breathing (SDB) in obese patients?. , 2018, , .		1
40	Variation in lung function as a marker of adherence to oral and inhaled medication in cystic fibrosis. European Respiratory Journal, 2017, 49, 1600987.	6.7	20
41	Definition of the Nature and Hapten Threshold of the Î²-Lactam Antigen Required for T Cell Activation In Vitro and in Patients. Journal of Immunology, 2017, 198, 4217-4227.	0.8	54
42	A treatment evaluator tool to monitor the real-world effectiveness of inhaled aztreonam lysine in cystic fibrosis. Journal of Cystic Fibrosis, 2017, 16, 695-701.	0.7	4
43	Update on primary ciliary dyskinesia. Paediatrics and Child Health (United Kingdom), 2017, 27, 337-342.	0.4	2
44	Diagnostic and prognostic significance of systemic alkyl quinolones for P. aeruginosa in cystic fibrosis: A longitudinal study; response to comments. Journal of Cystic Fibrosis, 2017, 16, e21.	0.7	3
45	Assessment of Antipiperacillin IgG Binding to Structurally Related Drug Protein Adducts. Chemical Research in Toxicology, 2017, 30, 2097-2099.	3.3	6
46	Detection of drugâ€responsive B lymphocytes and antidrug IgG in patients with Î²â€lactam hypersensitivity. Allergy: European Journal of Allergy and Clinical Immunology, 2017, 72, 896-907.	5.7	14
47	Diagnostic and prognostic significance of systemic alkyl quinolones for P. aeruginosa in cystic fibrosis: A longitudinal study. Journal of Cystic Fibrosis, 2017, 16, 230-238.	0.7	36
48	The burgeoning field of innate immuneâ€mediated disease and autoinflammation. Journal of Pathology, 2017, 241, 123-139.	4.5	62
49	Survival of Mycobacterium abscessus isolated from people with cystic fibrosis in artificially generated aerosols. European Respiratory Journal, 2016, 48, 1789-1791.	6.7	14
50	Implementing ICMH-CF (International Committee on Mental Health in CF) guidance on screening for depression and anxiety symptoms: A feasibility and pilot study. Journal of Cystic Fibrosis, 2016, 15, e33-e34.	0.7	8
51	Electronic patient records, past, present and future. Paediatric Respiratory Reviews, 2016, 20, 8-11.	1.8	8
52	Emergence and spread of a human-transmissible multidrug-resistant nontuberculous mycobacterium. Science, 2016, 354, 751-757.	12.6	462
53	Requirements and access needs of patients with chronic disease to their hospital electronic health record: results of a cross-sectional questionnaire survey. BMJ Open, 2016, 6, e012257.	1.9	7
54	Ultrasound and magnetic resonance imaging assessment of joint disease in symptomatic patients with cystic fibrosis arthropathy. Journal of Cystic Fibrosis, 2016, 15, e35-e40.	0.7	7

#	Article	IF	Citations
55	Fungal contamination of nebuliser devices used by people with cystic fibrosis. Journal of Cystic Fibrosis, 2016, 15, 74-77.	0.7	26
56	Pathogenicity of individual rhinovirus species during exacerbations of cystic fibrosis. European Respiratory Journal, 2015, 45, 1748-1751.	6.7	14
57	HLAâ€ÐQ alleleâ€restricted activation of nitroso sulfamethoxazoleâ€specific CD4â€positive T lymphocytes from patients with cystic fibrosis. Clinical and Experimental Allergy, 2015, 45, 1305-1316.	2.9	12
58	Characterization of Peroxidases Expressed in Human Antigen Presenting Cells and Analysis of the Covalent Binding of Nitroso Sulfamethoxazole to Myeloperoxidase. Chemical Research in Toxicology, 2015, 28, 144-154.	3.3	22
59	Presenting life with cystic fibrosis: a Qâ€methodological approach to developing balanced, experienceâ€based prenatal screening information. Health Expectations, 2015, 18, 1349-1362.	2.6	4
60	Systemic quorum sensing signal molecules are biomarkers for current and futureP. aeruginosainfection in cystic fibrosis patients: A longitudinal study. , 2015, , .		0
61	The role of respiratory viruses in adult patients with cystic fibrosis receiving intravenous antibiotics for a pulmonary exacerbation. Journal of Cystic Fibrosis, 2014, 13, 49-55.	0.7	54
62	Negative Regulation by PD-L1 during Drug-Specific Priming of IL-22â€“Secreting T Cells and the Influence of PD-1 on Effector T Cell Function. Journal of Immunology, 2014, 192, 2611-2621.	0.8	50
63	Negative regulation by Programmed Death Ligandâ€1 during drugâ€specific priming of Tâ€cells and the influence of Programmed Deathâ€1 on effector Tâ€cell function. Clinical and Translational Allergy, 2014, 4, O2.	3.2	0
64	Characterization of the TCR V repertoire of piperacillinâ€specific Tâ€cells. Clinical and Translational Allergy, 2014, 4, P39.	3.2	2
65	HLAâ€ÐQ restricted activation of nitrosoâ€sulfamethoxazoleâ€specific CD4+ Tâ€lymphocytes. Clinical and Translational Allergy, 2014, 4, P110.	3.2	0
66	Antigen exposure required for T cell activation. Clinical and Translational Allergy, 2014, 4, P115.	3.2	0
67	Isoniazidâ€specific Tâ€cell Responses in patients with antiâ€tuberculosis drug related liver injury. Clinical and Translational Allergy, 2014, 4, P116.	3.2	0
68	Reply to Professor Taylor. Journal of Cystic Fibrosis, 2014, 13, 486-487.	0.7	2
69	European Cystic Fibrosis Society Standards of Care: Framework for the Cystic Fibrosis Centre. Journal of Cystic Fibrosis, 2014, 13, S3-S22.	0.7	153
70	The development and deployment of integrated electronic care records in a regional adult and paediatric cystic fibrosis unit. Journal of Cystic Fibrosis, 2014, 13, 681-686.	0.7	16
71	Myocardial infarction in an adult with cystic fibrosis and heart and lung transplant. Multidisciplinary Respiratory Medicine, 2013, 8, 37.	1.5	3
72	Drug induced complications; can we do more?. Journal of Cystic Fibrosis, 2013, 12, 547-558.	0.7	11

#	Article	IF	Citations
73	Enteral tube feeding in adults with cystic fibrosis; patient choice and impact on long term outcomes. Journal of Cystic Fibrosis, 2013, 12, 616-622.	0.7	27
74	Î²-Lactam Antibiotics Form Distinct Haptenic Structures on Albumin and Activate Drug-Specific T-Lymphocyte Responses in Multiallergic Patients with Cystic Fibrosis. Chemical Research in Toxicology, 2013, 26, 963-975.	3.3	50
75	Decision Making about Risk of Infection by Young Adults with CF. Pulmonary Medicine, 2013, 2013, 1-6.	1.9	2
76	Nonimmediate Î²-lactam reactions in patients with cystic fibrosis. Current Opinion in Allergy and Clinical Immunology, 2012, 12, 369-375.	2.3	33
77	Characterization of the Antigen Specificity of T-Cell Clones from Piperacillin-Hypersensitive Patients with Cystic Fibrosis. Journal of Pharmacology and Experimental Therapeutics, 2012, 341, 597-610.	2.5	72
78	Challenges with current inhaled treatments for chronic Pseudomonas aeruginosa infection in patients with cystic fibrosis. Current Medical Research and Opinion, 2012, 28, 1059-1067.	1.9	12
79	Bloodstream infections in cystic fibrosis: Nine years of experience in both adults and children. Journal of Cystic Fibrosis, 2012, 11, 337-339.	0.7	10
80	Enhanced antigenicity leads to altered immunogenicity in sulfamethoxazole-hypersensitive patients with cystic fibrosis. Journal of Allergy and Clinical Immunology, 2011, 127, 1543-1551.e3.	2.9	43
81	Rapid desensitization for non-immediate reactions in patients with cystic fibrosis. Journal of Cystic Fibrosis, 2011, 10, 282-285.	0.7	39
82	Sequential Bronchoscopy in the Management of Lobar Atelectasis Secondary to Allergic Bronchopulmonary Aspergillosis. Journal of Bronchology and Interventional Pulmonology, 2011, 18, 57-60.	1.4	12
83	Pharmacokinetics of oral voriconazole in patients with cystic fibrosis. Journal of Antimicrobial Chemotherapy, 2011, 66, 2438-2440.	3.0	9
84	Mass Spectrometric Characterization of Circulating and Functional Antigens Derived from Piperacillin in Patients with Cystic Fibrosis. Journal of Immunology, 2011, 187, 200-211.	0.8	101
85	Accurate Assessment of Adherence. Chest, 2011, 140, 425-432.	0.8	179
86	Intrapleural Use of Tissue Plasminogen Activator and DNase in Pleural Infection. New England Journal of Medicine, 2011, 365, 518-526.	27.0	624
87	Hypogonadotropic hypogonadism: a consequence of Chiari-I malformation. Pituitary, 2010, 13, 183-185.	2.9	4
88	Isolation of the Fungus Geosmithia argillacea in Sputum of People with Cystic Fibrosis. Journal of Clinical Microbiology, 2010, 48, 2615-2617.	3.9	44
89	An aerobiological model of aerosol survival of different strains of Pseudomonas aeruginosa isolated from people with cystic fibrosis. Journal of Cystic Fibrosis, 2010, 9, 64-68.	0.7	21
90	Cystic fibrosis co-existing with trisomy 21. Journal of Cystic Fibrosis, 2010, 9, 330-331.	0.7	5

#	Article	IF	Citations
91	Drug Metabolite-Specific Lymphocyte Responses in Sulfamethoxazole Allergic Patients with Cystic Fibrosis. Chemical Research in Toxicology, 2010, 23, 1009-1011.	3.3	17
92	Investigating recurrent respiratory infections in primary care. BMJ: British Medical Journal, 2009, 339, b4118-b4118.	2.3	3
93	Routine screening for cystic fibrosis-related diabetes. Journal of the Royal Society of Medicine, 2009, 102, 36-39.	2.0	5
94	Nutritional decline in cystic fibrosis related diabetes: The effect of intensive nutritional intervention. Journal of Cystic Fibrosis, 2009, 8, 179-185.	0.7	39
95	Acute Burkholderia cenocepacia pyomyositis in a patient with cystic fibrosis. Journal of Cystic Fibrosis, 2009, 8, 273-275.	0.7	11
96	An unusual cause of subarachnoid haemorrhage in a patient with newly diagnosed neurofibromatosis: a case report. Cases Journal, 2009, 2, 8399.	0.4	1
97	A/H1N1 and other viruses affecting cystic fibrosis. BMJ: British Medical Journal, 2009, 339, b3958-b3958.	2.3	9
98	Serologic diagnosis of allergic bronchopulmonary aspergillosis in patients with cystic fibrosis through the detection of immunoglobulin G to Aspergillus fumigatus. Diagnostic Microbiology and Infectious Disease, 2008, 62, 287-291.	1.8	45
99	Ten years of viral and non-bacterial serology in adults with cystic fibrosis. Epidemiology and Infection, 2008, 136, 128-134.	2.1	20
100	Clinical impact of reducing routine susceptibility testing in chronic Pseudomonas aeruginosa infections in cystic fibrosis. Journal of Antimicrobial Chemotherapy, 2007, 61, 425-427.	3.0	25
101	Measurement of urinary N-acetyl-b-d-glucosaminidase in adult patients with cystic fibrosis: Before, during and after treatment with intravenous antibiotics. Journal of Cystic Fibrosis, 2007, 6, 67-73.	0.7	39
102	Therapeutic drug monitoring of once daily tobramycin in cystic fibrosisâ€"caution with trough concentrations. Journal of Cystic Fibrosis, 2007, 6, 125-130.	0.7	42
103	Recognition, clinical diagnosis and management of patients with primary antibody deficiencies: a systematic review. Clinical and Experimental Immunology, 2007, 149, 410-423.	2.6	194
104	Delayed diagnosis of cystic fibrosis associated with R117H on a background of 7T polythymidine tract at intron 8. Journal of Cystic Fibrosis, 2006, 5, 63-65.	0.7	35
105	Serum and sputum concentrations following the oral administration of linezolid in adult patients with cystic fibrosis. Journal of Antimicrobial Chemotherapy, 2004, 53, 325-328.	3.0	31
106	Effect of oral bisphosphonates on bone mineral density and body composition in adult patients with cystic fibrosis: a pilot study. Thorax, 2004, 59, 699-703.	5.6	18
107	Pharmacokinetics and safety of itraconazole in patients with cystic fibrosis. Journal of Antimicrobial Chemotherapy, 2004, 53, 841-847.	3.0	48
108	Treatment of resistant distal intestinal obstruction syndrome with a modified antegrade continence enema procedure. Journal of Cystic Fibrosis, 2004, 3, 273-275.	0.7	7

#	Article	IF	Citations
109	A pilot study of zafirlukast as an anti-inflammatory agent in the treatment of adults with cystic fibrosis. Journal of Cystic Fibrosis, 2003, 2, 25-28.	0.7	20
110	Burkholderia cepacia complex infection in adult patients with cystic fibrosisâ€"is early eradication possible?. Journal of Cystic Fibrosis, 2003, 2, 220-221.	0.7	15
111	Stenotrophomonas maltophilia contamination of nebulizers used to deliver aerosolized therapy to inpatients with cystic fibrosis. Journal of Hospital Infection, 2003, 55, 180-183.	2.9	56
112	Antibiotic Treatment of Multidrug-Resistant Organisms in Cystic Fibrosis. Treatments in Respiratory Medicine, 2003, 2, 321-332.	1.2	119
113	Steady-state pharmacokinetics of intravenous colistin methanesulphonate in patients with cystic fibrosis. Journal of Antimicrobial Chemotherapy, 2003, 52, 987-992.	3.0	159
114	The benefits of 3D modelling and animation in medical teaching. The Journal of Audiovisual Media in Medicine, 2002, 25, 142-148.	0.1	53
115	Macrolide antibiotics and cystic fibrosis. Thorax, 2002, 57, 189-190.	5.6	25
116	Type IV hypersensitivity to vitamin K. Contact Dermatitis, 2002, 46, 94-96.	1.4	15
117	Alcaligenes infection in cystic fibrosis. Pediatric Pulmonology, 2002, 34, 101-104.	2.0	76
118	Cystic fibrosis presenting as acute pancreatitis and obstructive azoospermia in a young adult male with a novel mutation in the CFTR gene. Pediatric Pulmonology, 2002, 34, 491-495.	2.0	10
119	Stenotrophomonas maltophilia Bacteraemia in Two Patients with Cystic Fibrosis Associated with Totally Implantable Venous Access Devices. Journal of Infection, 2002, 44, 53-55.	3.3	9
120	Na+/K+ATPase in Lower Airway Epithelium from Cystic Fibrosis and Non-Cystic-Fibrosis Lung. Biochemical and Biophysical Research Communications, 1997, 232, 464-468.	2.1	29
121	Is Burkholderia (Pseudomonas) cepacia disseminated from cystic fibrosis patients during physiotherapy?. Journal of Hospital Infection, 1996, 32, 9-15.	2.9	29
122	SHORT COMMUNICATION: Glutathione S-transferase GSTT1 genotypes and susceptibility to cancer: studies of interactions with GSTM1 in lung, oral, gastric and colorectal cancers. Carcinogenesis, 1996, 17, 881-884.	2.8	277
123	Nutritional status and pulmonary function in patients with cystic fibrosis with and without Burkholderia cepacia colonization: role of specialist dietetic support. Journal of Human Nutrition and Dietetics, 1996, 9, 173-179.	2.5	4
124	Na+ in cystic fibrosis: is it important?. Trends in Pharmacological Sciences, 1995, 16, 120-121.	8.7	3
125	Airborne dissemination of Burkholderia (Pseudomonas) cepacia from adult patients with cystic fibrosis.. Thorax, 1994, 49, 1157-1159.	5.6	35
126	Effect of antibiotic treatment on inflammatory markers and lung function in cystic fibrosis patients with Pseudomonas cepacia.. Thorax, 1994, 49, 803-807.	5.6	20

#	Article	IF	Citations
127	Machine Learning Predicts Acute Pulmonary Exacerbations in Cystic Fibrosis. SSRN Electronic Journal, 0, , .	0.4	3